Phathom Pharmaceuticals, Inc.
PHATHealthcareNASDAQBiotechnology · Last scanned Jun 2, 2026
Scan Results
Daily timeframePart of the healthcare sector, Phathom Pharmaceuticals, Inc. (PHAT) is listed under Biotechnology. At a $736.9M market cap, Phathom Pharmaceuticals, Inc. ranks as a small-cap company within healthcare. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Market Cap
$736.9M
Beta
0.57
P/E (TTM)
—
P/E (Fwd)
6.42
EPS (TTM)
$-2.09
EPS (Fwd)
$1.44
ROE
—
ROA
-20.2%
Cash
$180.9M
Total Debt
$547.2M
Free CF
-$77.5M
52W Change
86.7%
Annual Financials
Cash vs Debt
The company holds $180.9M in cash, though total debt stands at $547.2M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$77.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
PHAT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing PHAT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.